Quantum BioPharma Ltd. (QNTM) is a Toronto-based, clinical-stage biopharmaceutical company developing treatments for neurodegenerative, inflammatory and metabolic disorders, led by its multiple sclerosis candidate Lucid-MS, plus alcohol-misuse asset UNBUZZD and a 19.87% stake in Unbuzzd Wellness. The company generates no product revenue and is valued at roughly $12 million. Shares traded at $1.45 on Monday morning, down 9.94% from Friday's close of $1.61, a decline of $0.16. The move lower extended a four-session collapse that has taken the stock down about 35% from its Nov. 9 close of $2.23. No new company announcement was identified for Monday's session; the drivers were carryover selling after Friday's quarterly report and a renewed slide in digital-asset prices.
Friday's third-quarter filing gave investors little to buy. Quantum reported no revenue for the period, a nine-month net loss of roughly $17.32 million, and cash plus digital assets of about $12.22 million — enough, management said, to fund planned operations for the next twelve months. Operating expenses fell 32% year over year to $8.81 million and equity rose 91%, but the core issue for a sub-$15 million company is dilution math: a loss of that size against a small share count keeps pressure on the equity.
Shareholders also approved at the Nov. 10 annual meeting a slate of resolutions including authority for the board to consolidate shares at a ratio of up to 10-for-1 and to change the company's name. Both are discretionary and standard tooling for distressed small caps, but they reinforce the perception that the equity has been structurally impaired. A separate private placement of 26 Class A multiple voting shares lifted insider voting control to about 68.22%, leaving holders of the publicly traded Class B shares with limited influence. Each of those items was already known before Monday, which is why the decline reads as continuation rather than reaction.
Roughly 70% of Quantum's liquidity sits in digital assets — $8.66 million as of Sept. 30, up 127% since the start of the year. That accounting choice ties a large slice of book value to crypto pricing, and on Monday bitcoin-linked instruments were down about 6.5% in early trading. For a stock trading at a fraction of its reported equity base, a move of that size in the largest component of the balance sheet is a legitimate valuation headwind and is consistent with the acceleration in selling after the open.
The retreat was not isolated. The iShares Biotechnology ETF fell about 1.5%, the Russell 2000 small-cap proxy slipped roughly 1%, and the S&P 500 was off more than 1% as risk appetite weakened broadly. Volume was active but not exceptional: about 49,000 shares changed hands in the first hour against a full-day average near 170,000, with the heaviest blocks clustered in the opening 30 minutes when the stock touched an intraday low around $1.33.
Technically, the picture is broken. The stock trades far below its 20-, 50- and 200-day moving averages, near $2.20, $2.90 and $3.68 respectively, and the 14-day relative strength index has fallen deep into oversold territory. Monday's low marked a fresh 52-week bottom and the weakest level for the shares since late 2024. The stock is down roughly 78% year to date, having peaked above $12 within the past twelve months.
The score runs from 0 to 100, where 0 means no meaningful news and a routine price move, and 100 means transformative news paired with an extreme, rare move. Quantum BioPharma scores 28 out of 100.
The verified news was moderate: a quarterly report confirming ongoing losses, no revenue, and shareholder approval of reverse-split and name-change authority. All of it was material for a company this size, yet none of it was new on Monday. The price move, by contrast, was notable — about 2.6 times the stock's average absolute daily change of 3.8% over the past 60 sessions and the largest single-session percentage change in that span. Moderate news plus a meaningful but not extreme anomaly produces a below-midpoint score.
Attention turns to the Phase 2 start-up for Lucid-MS, run under an agreement with Thermo Fisher Scientific's clinical research business following August's FDA clearance of the investigational new drug application. Enrollment timing and trial costs will determine whether the current liquidity runway holds without another raise. Formal results are next expected with the fiscal 2026 year-end report in the first quarter of 2027.
The most immediate risk is listing-related: the shares only recently regained compliance with Nasdaq's $1 minimum bid price requirement, and a continued slide toward that level would revive that overhang. Analysts remain sparse, with a single Buy rating and an $8 price target published earlier this year that now sits far from the market. Sector risk appetite, biotech funding conditions and digital-asset prices all remain swing factors for a stock this thinly traded.
Tickeron's Trending AI Robots page curates the strongest-performing automated strategies under current market conditions from a library of hundreds of bots covering thousands of tickers. Because bots differ widely by strategy, timeframe, performance metrics and traded symbols, the trending list offers a practical starting point for comparing approaches side by side. Reviewing it alongside your own watchlist can help you see how systematic strategies are positioned right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where QNTM advanced for three days, in 198 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
QNTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QNTM as a result. In 61 of 65 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for QNTM turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 36 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 10-day moving average for QNTM crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QNTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for QNTM entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.142) is normal, around the industry mean (3.498). P/E Ratio (-0.469) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. QNTM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QNTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the production and processing of hydroponic indoor cannabis.
Industry Biotechnology